Roivant corrects Immunovant TED Phase 3 data timeline to H1 2025; reports Q4 revenue $27.4M, loss $0.05/share

Roivant Sciences Ltd.

Corrected timeline for Immunovant's Phase 3 TED trials: topline data expected in H1 2025 (previously misstated).
Q4 product revenue from VTAMA $13.7M; fiscal year VTAMA revenue $28.0M; over 170,000 prescriptions since launch.
Cash and equivalents $1.7B as of March 31, 2023; cash runway into H2 2025.
RVT-3101 Phase 2b UC data showed improved efficacy from week 14 to week 56; Phase 2 Crohn's study initiated.
Net loss attributable to Roivant $33.6M ($0.05 per share) for Q4 vs $270.1M loss year ago; loss from continuing ops $175.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2023.

Period: fourth quarter and fiscal year ended March 31, 2023
Result: reported results

Exact text from the filing

Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-031820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.